Citigroup
CVKD icon

Citigroup’s Cadrenal Therapeutics CVKD Stock Holding History

Citigroup’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5 Buy
+1
New +$7 ﹤0.01% 5775

Other funds holding CVKD

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
DWP
Destiny Wealth Partners Tavares, Florida $914M AUM 18.14% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Citigroup's CVKD Position: Q1 2026 in Review

Citigroup opened a new position in Cadrenal Therapeutics (CVKD) in Q1 2026: 1 share worth $5. The stake represents ﹤0.01% of the portfolio and ranks #5775 among its holdings.

20 funds tracked by Wall St. Rank hold CVKD as of Q1 2026.

  • Citigroup held 1 share of Cadrenal Therapeutics worth $5 as of Q1 2026.
  • Cadrenal Therapeutics was a new Citigroup position in Q1 2026.
  • Cadrenal Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5775 holding.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.